# Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Source: https://onco.cc/trials/nct07085767/  
OnCo record `nct07085767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ribociclib in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., now recruiting.

## Summary

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT07085767 by Olema Pharmaceuticals, Inc., with 1000 participants planned, started 2025-11-03 and due to reach its primary completion in 2028-12. Interventions recorded: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole and Palazestrant matching-placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07085767
- Phase: 3
- Setting: A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
- Sponsor: Olema Pharmaceuticals, Inc.
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT07085767: https://clinicaltrials.gov/study/NCT07085767

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/), [Olema Pharmaceuticals](https://onco.cc/companies/olema-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07085767.json